Mannkind Corporation (MNKD) is a publicly traded Healthcare sector company. As of May 21, 2026, MNKD trades at $3.29 with a market cap of $923.76M and a P/E ratio of -45.64. MNKD moved +9.46% today. Year to date, MNKD is -42.17%; over the trailing twelve months it is -25.37%. Its 52-week range spans $2.23 to $7.63. Analyst consensus is strong buy with an average price target of $7.54. Rallies surfaces MNKD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
MannKind Q1 Revenues Rise 15% to $90.2M; PDUFA Dates for Afrezza Pediatric and Furoscix ReadyFlow: MannKind reported Q1 2026 revenues of $90.2M, up 15% year-over-year on $15.5M in Furoscix net sales (64% dose growth) and $32.7M in royalties. The company settled $36.3M of convertible notes, received $5M from United Therapeutics for ralinepag DPI and targets PDUFA dates of May 29 and July 26.
| Metric | Value |
|---|---|
| Price | $3.29 |
| Market Cap | $923.76M |
| P/E Ratio | -45.64 |
| EPS | $-0.07 |
| Dividend Yield | 0.00% |
| 52-Week High | $7.63 |
| 52-Week Low | $2.23 |
| Volume | 6.98K |
| Avg Volume | 0 |
| Revenue (TTM) | $360.78M |
| Net Income | $-23.91M |
| Gross Margin | 91.53% |
8 analysts cover MNKD: 0 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $7.54.